Eli Lilly & Co.’s bid for accelerated approval of its Alzheimer’s remedy donanemab was rejected by U.S. regulators, an surprising setback for the drugmaker.
The Meals and Drug Administration despatched the corporate a whole response letter saying it might not give the early approval for the drug as a result of not sufficient sufferers on the trial had acquired it for a full 12 months, Lilly mentioned Thursday in an announcement.
The company needed Lilly to offer security information on a minimum of 100 sufferers who had been on the drug for a yr. Lilly’s software for accelerated approval was based mostly on a comparatively small mid-stage trial that allowed some sufferers to cease therapy after about six months.
“No different deficiencies had been recognized,” the corporate mentioned.
The setback gained’t have an effect on the corporate’s 2023 monetary steering or its plans to use for normal approval for the drug later this yr if an ongoing final-stage trial is profitable, Lilly mentioned. The corporate expects these ends in the second quarter.
Lilly shares fell as a lot as 1.9% on the New York market open.
Little Gross sales Affect
Accelerated approval was by no means anticipated to result in important gross sales. The U.S. Medicare program has indicated that it gained’t broadly cowl amyloid-lowering Alzheimer’s medicine like donanemab with out full FDA approval.
Nonetheless, Lilly officers had hoped to realize early approval for the drug. Rival Eisai Co. and accomplice Biogen Inc. obtained accelerated approval for his or her amyloid-lowering drug Leqembi earlier this month, and have already utilized for full clearance.
“It’s an uncommon state of affairs,” Lilly Chief Scientific and Medical Officer Daniel Skovronsky mentioned in an interview. The corporate’s drug was fairly efficient at eradicating amyloid within the mid-stage trial, he mentioned. Some sufferers stopped taking it after a number of months as a result of their amyloid ranges had fallen to date. Others who responded extra slowly continued on it for greater than a yr. If the drug had been much less efficient, the corporate wouldn’t have confronted this situation, he mentioned.
Hopes for donanemab had been excessive after an earlier evaluation of the trial confirmed the drug slowed cognitive decline by 32%. Nonetheless, individuals additionally had a 39% price of mind swelling or bleeding in comparison with 8% of these on a placebo. In the meantime, Eisai’s Leqembi slowed cognitive and practical decline by 27%. That drug gained FDA accelerated approval based mostly on its skill to decrease amyloid.
“The precedence after all is to get the standard approval,” mentioned Skovronsky, who didn’t rule out the likelihood the corporate might nonetheless return and search accelerated approval as soon as it obtained extra security information. “All the pieces relies on our part 3 trial.”
On Friday, Lilly and Boehringer Ingelheim reported extra information from the FDA, saying the regulator accepted a supplemental new drug software for Jardiance. The diabetes drug, one among Lilly’s high sellers, is in testing for lowering the chance of kidney illness development and heart-related deaths in grownup continual kidney illness sufferers.
—With help from Jonathan Roeder.
Extra Should-Reads From TIME